After a commendable run in the first nine months of 2024, the S&P 500 is poised to gain in the year’s final three months. The S&P 500 has risen 20.8% in the first three quarters of the year, and historically whenever the broader index has gained over 20%, it has, on average, risen 2.1% in the fourth quarter, per Dow Jones Market Data.In the October-December quarter, the S&P 500’s median return was as high as 4.1%, and the index gained more than 77% of the time, added Dow Jones Market Data.The Federal Reserv ...

Company Performance - Boston Scientific (BSX) closed at $84.49, with a +0.42% change from the previous day's closing price, outperforming the S&P 500 which gained 0.01% [1] - Over the last month, Boston Scientific's shares increased by 3.7%, while the Medical sector experienced a loss of 3.6% and the S&P 500 gained 1.21% [1] - The company is expected to report an EPS of $0.58, reflecting a 16% increase from the same quarter last year, with a projected quarterly revenue of $4.03 billion, up 14.36% year-over-year [1] Full Year Estimates - For the full year, earnings are projected at $2.40 per share and revenue at $16.26 billion, indicating increases of +17.07% and +14.22% respectively from the previous year [2] Analyst Sentiment - Recent changes to analyst estimates for Boston Scientific indicate positive sentiment, suggesting optimism regarding the company's business and profitability [2] - The Zacks Rank system currently rates Boston Scientific at 2 (Buy), with a historical average annual return of +25% for 1 rated stocks since 1988 [3] Valuation Metrics - Boston Scientific has a Forward P/E ratio of 35.05, compared to the industry average of 24.52, indicating it is trading at a premium [3] - The company has a PEG ratio of 2.79, while the Medical - Products industry has an average PEG ratio of 2 [3] Industry Overview - The Medical - Products industry is part of the Medical sector and holds a Zacks Industry Rank of 50, placing it in the top 20% of over 250 industries [4] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [4]

Boston Scientific’s (BSX) growth is backed by its successful expansion of operations across different geographies outside the United States. Its recent acquisitions are expected to drive revenue growth in the long term. Consistent MedSurg market share gain is also highly encouraging. Meanwhile, headwinds such as currency movements raise concern for Boston Scientific.In the past year, this Zacks Rank #2 (Buy) company’s shares have rallied 63.3% compared with the industry’s 26.5% growth and the S&P 500 compos ...

-Company to also host virtual webcast with a cardiology business update-MARLBOROUGH, Mass., Oct. 2, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2024, on Wednesday, October 23, 2024, at 8:00 a.m. ET. The call will be hosted by Mike Mahoney, chairman and chief executive officer, and Dan Brennan, executive vice president and chief financial officer. The company will ...

MedTech manufacturers, who were literally hankering for the easing of monetary policy following a prolonged period of challenging business scenarios, probably heaved a sigh of relief after September’s aggressive rate cut. The highly-anticipated 50-bps rate cut by the Fed, bringing the federal funds rate to a 4.75% to 5% target range, is considered a turning point in overcoming the ongoing challenges of a period of decline and decadence within the MedTech space.With a high probability of another half a perce ...

Boston Scientific Corporation (BSX) recently received the Pharmaceuticals and Medical Device Agency’s (“PMDA”) approval in Japan for its FARAPULSE Pulsed Field Ablation (“PFA”) System. The FARAPULSE PFA System is used for treating paroxysmal atrial fibrillation (AF).Boston Scientific expects to launch the FARAPULSE PFA System in Japan in the upcoming weeks to treat approximately 1 million people affected by AF.BSX’s Likely Stock Trend Following the NewsSubsequent to the announcement, shares of BSX moved nor ...

The most recent trading session ended with Boston Scientific (BSX) standing at $83.08, reflecting a -0.5% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain of 0.4%. On the other hand, the Dow registered a gain of 0.62%, and the technology-centric Nasdaq increased by 0.6%.Coming into today, shares of the medical device manufacturer had gained 5.01% in the past month. In that same time, the Medical sector lost 2.27%, while the S&P 500 gained 1.71%.The investment communi ...

The latest trading session saw Boston Scientific (BSX) ending at $84, denoting a +0.1% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.28%. Elsewhere, the Dow saw an upswing of 0.15%, while the tech-heavy Nasdaq appreciated by 0.15%.Shares of the medical device manufacturer witnessed a gain of 6% over the previous month, beating the performance of the Medical sector with its gain of 0.38% and the S&P 500's gain of 2%.Analysts and investors alike will b ...

Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth stock is not easy at all.That's because, these stocks usually carry above-average risk and volatility. In fact, betting on a stock for which the growth story is actually over or nearing its end could lead to significant loss.However, the Zacks Growth Style Score (part of the Zacks Style Scores system), which looks ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...